From 3rd to 5th July, the 15th China Dairy Industry Conference, the 2024 China Dairy D20 Summit and the China Dairy Industry Exhibition were held in Wuhan, Hubei Province. During the event, the China Dairy Association formally announced the list of “Major Scientific and Technological Innovation Achievements in the Dairy Industry”. Synaura Biotech was honoured with the “2024 Major Scientific and Technological Innovation Achievement Award in Dairy” for its project “Breakthrough Production Technology and Application of Human Milk Oligosaccharides (HMOs)”, once again receiving high recognition from the industry. The ‘Major Scientific and Technological Innovation Achievement Award in Dairy Industry’ aims to fully explore and showcase outstanding achievements in dairy industry innovation, foster a favourable innovation ecosystem, promote the application and dissemination of scientific and technological innovations, advance technological progress and industrial upgrading within the sector, and enhance the overall competitiveness of the dairy industry. Certificate for the 2024 Major Scientific and Technological Innovation Achievement Award in the Dairy Industry As China's leading domestic HMO producer, Synaura Biotech employs advanced synthetic biology techniques to achieve efficient and safe HMO production through microbial fermentation. The bacterial strains undergo rigorous screening and safety assessments, meeting National Health Commission standards and establishing a robust foundation for exceptional product quality. Synaura Biotech is wholly committed to advancing compliant domestic production. With an ingenious spirit, it continuously refines production processes and perfects products, striving to deliver HMOs characterised by uniform particle size, high purity, purity without odour, and exceptional value for money. Authoritative third-party testing has confirmed that Synaura HMO possesses the same structural composition as breast milk HMO*. Extensive customer validation has demonstrated that Synaura's HMOs have gained widespread market recognition for their exceptional quality, ease of application, and adaptability to diverse production methods including dry and wet processes. This accolade not only acknowledges Synaura's relentless exploration and innovation within the HMO field but also serves as compelling evidence of its immense potential in driving technological advancement and spearheading industrial upgrading within the sector. Looking ahead, Synaura Biotech remains steadfast in its commitment to deepening expertise within the HMO domain. Through continuous exploration of novel technologies and methodologies, the company will deliver increasingly superior products and services. This endeavour aims to bolster the high-quality development of China's dairy industry and contribute sustainably to the nation's health objectives. *The verification results are derived from authoritative third-party scientific data.

Recently, the Foodaily FBIC 2024 Innovation Conference commenced as scheduled at the National Exhibition and Convention Centre (Shanghai). Centred on the theme ‘Breaking Through the Industrial Chain, Co-Creating New Horizons’, the event featured multiple segments including plenary summits, category & thematic forums, and global innovation tastings. Concurrently, the ‘Foodaily 2024 Daily Food Innovation Expo’ and the ‘iSEE Innovation Gala & iSEE Golden Awards Ceremony’ were held. As China's leading HMO innovator, Synaura Biotech was invited to present at the conference's thematic forum and attended the ‘iSEE Innovation Gala and iSEE Golden Awards Ceremony’ as recipient of the ‘Global Food Innovation Technology Award’. Synaura Biotech Honoured with iSEE Global Food Innovation Technology Award As an authoritative award with global influence in the food and beverage industry, the iSEE Global Awards have consistently dedicated themselves to discovering and recognising pioneering innovative enterprises and culinary products worldwide since their inception. To date, they have attracted over 10,000 case submissions. This year's iSEE Global Awards expanded its reach to encompass China, Japan, South Korea, Europe and other regions, gathering a diverse array of innovative participants including international giants, leading local enterprises, traditional brands undergoing transformation, and pioneering newcomers. Figure 1: iSEE Awards Ceremony On 9 May, the iSEE Innovation Gala and iSEE Golden Awards Ceremony concluded successfully, with over 1,000 industry leaders and top media outlets witnessing the unveiling of the 2024 iSEE Global Awards. According to organisers' statistics, this year's global awards attracted over 3,000 brand entries and 4,000 case submissions. Following online preliminary selection and offline initial and final reviews by the organising committee's expert panel, only 50 food innovation technology entries advanced to the final judging stage. As a pioneer in China's HMO sector, Synaura Biotech distinguished itself among over 4,000 domestic and international entries. Its proposal, ‘Microbial Fermentation Method for Preparing 2'-Fucosyllactose (2'-FL) and Its Industrial Applications,’ was honoured with the 2024 iSEE Global Food Innovation Technology Award. This achievement not only demonstrates Synaura Biotech's exceptional innovation capabilities within the HMO sector but also showcases the outstanding innovative accomplishments of domestic Chinese enterprises to the entire industry and consumers. Figure 2: Synaura Award Certificate Additionally, Synaura Biotech was invited to participate in the ‘iSEE Global Awards Technology Innovation Gallery’, showcasing its position as an exemplary innovative technology enterprise at the conference venue. Throughout the exhibition period, the stand attracted a steady stream of visitors, with numerous attendees and industry experts demonstrating keen interest in Synaura's innovative technologies and product solutions, pausing frequently to seek further information. Zhang Xiaowei, Head of Business Development at Synaura, represented the company during a live interview broadcast from the ‘iSEE Technology Gallery’, sharing insights with online audiences on Synaura Biotech's technological advantages as China's leading HMO innovator within the synthetic biology sector. Figures 3 and 4: Synaura Exhibition Stand Layout Keynote Address at the Forum On the afternoon of 10 May, Ms Yao Fei, Head of Applied R&D at Synaura Biotech, represented the company as an invited speaker at the ‘Dairy Innovation’ category forum. She delivered a presentation entitled ‘Synthetic Biology: The New Productivity in Food Production Starts with HMOs’. Ms Yao Fei addressed the audience by focusing on novel food production capabilities, highlighting the significant role of artificial intelligence and synthetic biology in driving innovation within the food sector. Using HMOs as a prime example, she provided a detailed overview of global research achievements and current applications, while offering a comprehensive outlook on future development prospects. Figure 5: Scene from the presentation This invitation and accolade not only underscore the high regard held by both industry insiders and outsiders for Synaura Biotech's scientific research capabilities and innovative achievements, but also serve as compelling evidence of the company's robust technical prowess in the independent development of HMO products. It demonstrates the exceptional capabilities of a Chinese domestic enterprise within the HMO field. Synaura's 2'-FL is produced using advanced microbial fermentation technology, renowned for its uniform particle size, high purity (≥96%), and absence of residual acetic acid odour. Authoritative third-party testing has confirmed that Synaura's HMO products possess identical structural composition to breast milk HMOs*. Figure 6: Five Key Advantages of Synaura™ HMO Through extensive application validation by numerous clients, Synaura Biotech's HMO has gained widespread market recognition for its exceptional quality, user-friendly application, and high adaptability to diverse production processes including dry and wet methods. Moving forward, Synaura Biotech remains steadfast in its founding mission, continuously driving technological innovation within the food sector to provide healthier, safer choices for millions of households. *The verification results are derived from authoritative third-party scientific data.

Recently, Synaura Biotech (Shanghai) Co., Ltd. (‘Synaura Biotech’) has successfully secured nearly 100 million yuan in Pre-A round financing. This funding round was led by CICC Qide Fund, under the renowned investment institution CICC Capital, with participation from Moutai Fund. The capital raised will be allocated towards new product development, laboratory construction, industrialisation implementation, and commercialisation advancement, injecting fresh momentumSynaura Biotech's innovative development within the HMO sector. Established in February 2022, Synaura Biotech stands as China's pioneering domestic HMO innovator, spearheading future nutritional trends with its proprietary HMO products. Its HMO offerings set new benchmarks in health nutrition through exceptional properties including high purity, low impurity levels, and odourlessness. Leveraging cutting-edge R&D capabilities and precision fermentation techniques, Synaura Biotech delivers solutions that meet both client innovation requirements and consumer demands for premium nutritional quality. Dr Huang Xu, Managing Director of CICC Capital, remarked that HMOs have been a key focus for numerous dairy enterprises in recent years. Following formal approval in October 2023, they will spearhead a new wave of advancement within the infant formula and dairy sectors. As China's first approved enterprise, Synaura Biotech is poised to seize opportunities in the global nutritional supplements market and soar to new heights, bolstered by shareholder resources and driven by its dedicated management team. Maotai Fund serves as the market-oriented equity investment platform under China Kweichow Moutai (Group) Co., Ltd. (‘Maotai Group’). Focusing on cutting-edge developments and applications in biotechnology, Maotai Fund has recognised Synaura Biotech's growth potential within the synthetic biology sector. Existing shareholder Beihai Mengniu Venture Capital has made a follow-on investment in this round. As a wholly-owned incubator platform under Mengniu Group and a key component of its strategic investment arm, Beihai Mengniu Venture Capital participated in Synaura Biotech's founding through investment and incubation. This additional investment underscores Mengniu's confidence and commitment to its strategic positioning in the synthetic biology sector. Moving forward, with the combined strengths of all shareholders, Synaura Biotech will accelerate the development of its R&D innovation capabilities. The company will prioritise the development of HMOs and new pipelines, further enhance its local HMO expertise and influence, continuously cultivate new productive forces, and contribute to the high-quality development of the dairy industry. About CICC Capital CICC Capital serves as the private equity fund management platform of China International Capital Corporation Limited (‘CICC’), overseeing the firm's domestic and international private investment fund operations. It has evolvedone of China's leading private investment management institutions. Currently, the funds under its management encompass RMB corporate equity funds, fund-of-funds, real estate funds, infrastructure funds, and USD corporate equity funds.

From 24th to 26th April, the 2024 International Food Safety and Health Conference (IFoFSH 2024), jointly organised by the Chinese Institute of Food Science and Technology and the Internationalof Food Science and Technology, convened in Beijing. Synaura Biotech, as China's leading HMO innovator, was invited to participate and delivered a presentation on the topic of ‘Management and Innovative Application Technologies for Functional Ingredients’. Figure 1: 2024 International Forum on Food Safety and Health Figure 2: Live footage from the conference venue As an authoritative international gathering in the field of food safety and health, the Food Safety and Health Conference has consistently enjoyed strong support from relevant national authorities including the State Administration for Market Regulation, the Ministry of Industry and Information Technology, and the Ministry of Agriculture and Rural Affairs, alongside international organisations such as the World Health Organisation (WHO) and the Food and Agriculture Organisation (FAO). This conference brings together hundreds of experts and scholars from the food science and technology community and industry, alongside distinguished corporate representatives from both domestic and international spheres. Participants will collectively focus on technological innovation, engaging in intellectual exchange across nine thematic forums centred on the theme ‘New Quality Productivity: Advancing Health and Safety to Higher Standards’. Together, they will chart a course for the high-quality development of the food industry. Figure 3: Ms Yao Fei delivering her presentation Ms Yao Fei, Head of Applied Research and Development at Synaura Biotech, delivered a presentation entitled ‘Global Research and Application Landscape of HMOs’ on behalf of the company. The report traced the developmental trajectory of HMOs, offering an in-depth analysis of global research achievements, relevant patents, and current market applications both domestically and internationally. Furthermore, Ms Yao engaged with conference attendees in exploring the innovative application prospects of HMOs across global sectors including food, cosmetics, and healthcare. Figure 4: Illustrating the Five Key Advantages of Synaura™ HMO Synaura Biotech is China's leading indigenous developer and industrialiser of human milk oligosaccharides (HMOs), while also pioneering advancements in synthetic biology through mastery of cutting-edge synthetic biology technologies. Presently, Synaura has successfully established over ten distinct product lines spanning biomedicine, sustainable agriculture, and health foods. Extensively validated through practical applications, Synaura's HMOs are renowned for their superior quality, characterised by high purity, uniform particle size, and absence of acetic acid odour residue. Their adaptability to both dry and wet processing methods ensures application convenience. Synaura Biotech remains committed to independent innovation and industrial practice, dedicated to providing high-quality HMO raw materials to hundreds of millions of Chinese families, delivering enhanced health and care.

On 20 March, the 27th China International Food Ingredients China (FIC 2024) commenced in grand style at the National Exhibition and Convention Centre in Shanghai. Making its debut at FIC as China's pioneering domestic HMO leader, Synaura Biotech captured significant attention from numerous attendees. Synaura Innovation Symposium That morning, the Synaura Biotech Innovation Symposium brought together experts from diverse fields to share new developments in HMOs within the food sector with attendees. Mr He Yuanchao, CEO of Meow Factory and innovation specialist, delivered a presentation titled ‘The Path to Innovation in Infant Nutrition in the Era of Precision Feeding’. From a brand marketing perspective, he elaborated on how HMOs can play a pivotal role in precision feeding within the current context of transformation and upgrading in the infant nutrition industry. Professor Li Chun from Northeast Agricultural University delivered a presentation entitled ‘Research on the Efficacy of Human Milk Oligosaccharides: Gut, Immunity and Allergy’. The presentation provided an in-depth overview from a scientific perspective of research findings concerning the role of HMOs in enhancing gut health, boosting immunity and preventing allergies. In the ‘Global Application Scan of Human Milk Oligosaccharides (HMOs)’ report, Ms Yao Fei, Head of Application R&D at Synaura Biotech, shared with attendees the current global application landscape and innovative prospects for HMOs across the food, cosmetics and healthcare sectors. Dr Zhang Hanzhi, Chief Testing Officer at Synaura Biotech, delivered an in-depth presentation on ‘HMO Detection Methods and Analysis of Common Issues’ from a testing perspective. The presentation covered cutting-edge knowledge in HMO detection technology, analysed common challenges encountered in current testing processes, and provided valuable industry insights. Strategic Cooperation Signing Ceremony Furthermore, attendees witnessed the signing ceremony for the strategic cooperation between Synaura Biotech (Shanghai) Co., Ltd. and Xi'an Libang Clinical Nutrition Co., Ltd. This significant moment symbolises the shared vision of Synaura Biotech and its partners within the HMO sector, representing a firm stride forward on their future development path. Synaura Exhibition Stand At the exhibition stand, visitors demonstrated considerable enthusiasm for Synaura's comprehensive solutions, pausing frequently to enquire. FIC2024 represents another significant milestone in Synaura Biotech's development journey. With the successful conclusion of the exhibition, Synaura Biotech will achieve further innovations in the HMO field, making greater contributions to global nutrition and health initiatives.

Recently, Mengniu Ruibuen officially launched its inaugural human milk oligosaccharide (HMO) formula milk powder—Ruibuen Enzhi Stage 4—injecting fresh vitalitythe infant nutrition sector. This innovative product incorporates Synaura™ HMO, a human milk oligosaccharide independently developed by Synaura Biotech. This ingredient received approval from China's National Health Commission on 7 October 2023, making Synaura Biotech the sole domestic Chinese enterprise among the first batch of approved companies. This milestone achievement not only underscores Synaura Biotech's leading position in the field of ‘domestic independent research and development,’ but also demonstrates its outstanding contributions to technological innovation in infant nutrition. Breaking Through Industrial Barriers Through Independent R&D Human milk oligosaccharides (HMOs) constitute the third most abundant solid component in breast milk after lactose and fat, playing a crucial role in promoting immune regulation, cognitive development, and gut health in infants and young children. The health benefits of HMOs have been substantiated by numerous fundamental and clinical studies, with their significance for infant growth and development now widely recognised within the industry. Aware of HMOs' pivotal role, global infant formula giants have long pursued intensive research. For years, industrial-scale HMO production technology remained firmly in the hands of Western conglomerates, creating a critical bottleneck that stifled China's domestic HMO raw material development and production. This constraint has also hampered the high-quality advancement of China's dairy industry. Against this backdrop, Synaura Biotech's breakthrough innovation proves particularly significant and encouraging. The phrase ‘domestically developed’ carries substantial weight in Synaura's case, as the industrial application of HMOs propels China's dairy sector forward on its path towards high-quality development. Rigorous refinement for exceptional performance Synaura Biotech's strengths in HMO research extend beyond domestic R&D capabilities to industry-leading product performance. Laboratory data demonstrates that Synaura's proprietary HMOs achieve high purity, minimal impurities and odourlessness. This data not only validates the high standards and exceptional performance of Synaura's independently developed HMOs, but also provides robust quality assurance for domestic dairy products, driving the industry towards higher quality standards. The Five Key Advantages of Synaura™ HMO Continuously Empowering Cutting-Edge Breakthroughs Tracking the industry's developmental trajectory, China's infant formula sector has progressed from an initial phase of balanced supplementation with fundamental nutrients (such as proteins, fats, carbohydrates, vitamins, and minerals), through an enhancement stage featuring representative nutrients like DHA, lactoferrin, and OPO, to its current comprehensive adoption of HMO technology. Through the continuous advancement and collective efforts of Chinese biotechnology companies like Synaura Biotech, more innovations and scientific discoveries will be translatedpractical applications, propelling China's infant formula industry towards a path of high-quality development.